Drug Trial Radar · NCT04021368
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
51
Actual
Start
Sep 4, 2019
Primary completion
May 21, 2024
Study completion May 21, 2024
Sponsor
- Lead sponsor
- Ryvu Therapeutics SAIndustry
- Sponsor type
- Industry
- First posted
- Jul 16, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human study will evaluate RVU120 (SEL120), a novel small molecule CDK8/19 inhibitor, in patients with Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (HR-MDS), in terms of selection of the recommended dose for further clinical development and assessment of safety, tolerability, preliminary anti-leukemic activity, as well as pharmacokinetic and pharmacodynamic profiles.
Conditions
- Acute Myeloid Leukemia
- High-risk Myelodysplastic Syndrome
Interventions
RVU120(SEL120)Drug
RVU120(SEL120) will be administered as a single oral dose every other day (q.o.d.) for a total of 7 doses i.e. on Days 1, 3, 5, 7, 9, 11 and 13, in a 3-week treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended dose (RD)Time frame: Up to 2 years
- Incidence of Adverse Events (Safety and Tolerability)Time frame: Up to 2 years
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics
Miami, Florida
Northside Hospital
Atlanta, Georgia
Washington University School of Medicine
St Louis, Missouri
Tennessee Oncology
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
MICS Centrum Medyczne Toruń
Torun, Poland
Instytut Hematologii i Transfuzjologii
Warsaw, Poland
Dolnośląskie Centrum Onkologii, Pulmonologii i Hematologii
Wroclaw, Poland
Świętokrzyskie Centrum Onkologii, Klinika Hematologii i Transplantacji Szpiku
Kielce, Świętokrzyskie Voivodeship, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.